Skip to main content
Premium Trial:

Request an Annual Quote

FDA Asks Clinical Data to Discuss Regulatory Status of Its Tests

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has asked Clinical Data to “discuss the nature and appropriate regulatory status” of the company’s diagnostic tests, Clinical Data said today.
Specifically, the firm and the FDA will discuss whether “any regulatory requirements apply, [and] the least burdensome ways that the company may fulfill them,” Clinical Data said.
The company said it plans to meet with the FDA “in the near future.”
“The company looks forward to meeting with the FDA and reviewing the regulatory status for all tests conducted on behalf of end-users including FAMILION, its CLIA-certified test for cardiac channelopathies that requires a prescription by healthcare providers,” Clinical Data said in a statement.
“Clinical Data notes that while it conducts DNA assays for one nutrigenomic test on behalf of a third party customer, the test is not marketed by Clinical Data and revenue from this test is immaterial” to its business, the company said.
“The company believes it is in compliance with all applicable state and federal regulations and will continue to work with the appropriate regulatory agencies to remain so,” Clinical Data said.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.